DODOMA — 20 October 2026. Tanzania’s health minister, Mohamed Mchengerwa, has directed the Tanzania Medicines and Medical Devices Authority to link its information systems with the National Health Insurance Fund so medicines can be checked before insurance claims are approved.
The Citizen’s report from Dodoma attributes the direction to his remarks at the inauguration of TMDA’s Advisory Board on Monday, 19 October. He said health insurance should not pay for medicines unregistered by the authority.
For patients, this raises two separate questions: whether a medicine has regulatory authorisation and whether a particular insurance plan covers it. Both need clear answers from the provider and insurer.
What does Tanzania’s medicine-payment directive mean? The health minister wants TMDA and NHIF systems connected so medicine registration can be verified before insurance claims are approved. Patients should ask providers about the exact product and their insurer about coverage. The reported direction does not establish a verified nationwide switch-on date.
Registration and insurance coverage are different checks
The minister’s direction concerns product verification before payment. A patient asking about a prescription should first identify the medicine precisely, including its name, strength, dosage form and manufacturer. Those details help the pharmacy distinguish the prescribed product from another with a similar name.
Insurance coverage is a further question. Ask the insurer whether the specific medicine is covered under the relevant benefit and whether any approval is required. A provider’s statement that a product is registered should not be taken as a guarantee that every insurance plan will pay for it.
Similarly, a payment dispute should be explained in writing where possible. Ask whether the issue concerns registration, the benefit package, prior approval, missing documentation or another administrative matter. The explanation determines which institution can resolve it.
What TMDA already says about authorisation
TMDA’s emergency-use authorisation guidelines explain its mandate to regulate medicine quality, safety and efficacy. The guidelines also describe circumstances in which unregistered medicines may receive specific authorisation during a declared public-health emergency.
PUBLIC HEALTH ALERTS
Tanzania Medicine Claims: What the Registration Directive Means
Oct 20, 2026
Oct 20, 2026
5 min read
Published
Updated:
DODOMA — 20 October 2026. Tanzania’s health minister, Mohamed Mchengerwa, has directed the Tanzania Medicines and Medical Devices Authority to link its information systems with the National Health Insurance Fund so medicines can be checked before insurance claims are approved.
The Citizen’s report from Dodoma attributes the direction to his remarks at the inauguration of TMDA’s Advisory Board on Monday, 19 October. He said health insurance should not pay for medicines unregistered by the authority.
For patients, this raises two separate questions: whether a medicine has regulatory authorisation and whether a particular insurance plan covers it. Both need clear answers from the provider and insurer.
What does Tanzania’s medicine-payment directive mean? The health minister wants TMDA and NHIF systems connected so medicine registration can be verified before insurance claims are approved. Patients should ask providers about the exact product and their insurer about coverage. The reported direction does not establish a verified nationwide switch-on date.
Registration and insurance coverage are different checks
The minister’s direction concerns product verification before payment. A patient asking about a prescription should first identify the medicine precisely, including its name, strength, dosage form and manufacturer. Those details help the pharmacy distinguish the prescribed product from another with a similar name.
Insurance coverage is a further question. Ask the insurer whether the specific medicine is covered under the relevant benefit and whether any approval is required. A provider’s statement that a product is registered should not be taken as a guarantee that every insurance plan will pay for it.
ADVERTISEMENT
Similarly, a payment dispute should be explained in writing where possible. Ask whether the issue concerns registration, the benefit package, prior approval, missing documentation or another administrative matter. The explanation determines which institution can resolve it.
What TMDA already says about authorisation
TMDA’s emergency-use authorisation guidelines explain its mandate to regulate medicine quality, safety and efficacy. The guidelines also describe circumstances in which unregistered medicines may receive specific authorisation during a declared public-health emergency.
That regulatory framework makes the precise authorisation status important. Registration and a specific emergency permission are not identical. The reported insurance direction does not explain how exceptional authorisations will be handled; providers and insurers should clarify any such case rather than leaving a patient to interpret it.
TMDA’s site links to its customer self-service portal for regulated-product services. Patients who cannot establish a product’s status should ask a pharmacist or TMDA for assistance with the exact product details. A failed online search alone is insufficient to determine that a product is unlawful: names, presentation and database access may affect what a search returns.
ADVERTISEMENT
The Attorney General’s official legislation database also records a 2024 notice concerning registered medicines. That dated notice is part of the regulatory record; it should not be treated as a complete current answer for every product in October 2026.
Essential medicines lists answer another question
The World Health Organization hosts Tanzania’s 2026 National Essential Medicines List, on a publication page dated 9 September 2026.
An essential medicines list, product registration and an insurance benefit package serve different purposes. Patients should ask which rule the provider is applying, rather than assuming these documents are interchangeable. A medicine’s inclusion on a list does not, by itself, settle the registration or payment status of every branded product containing it.
For an individual prescription, the safest route through that administrative question is to speak with the treating clinician, pharmacist and insurer. Do not replace a prescribed medicine or interrupt treatment solely because of an online insurance headline.
Keep the documents needed to resolve a claim
If payment is refused or delayed, retain the prescription, invoice, receipt, insurer’s explanation and relevant product packaging. Record the date, facility and claim reference. Ask the provider and insurer which document or clarification is needed next.
Trending Now
Popular Today
ADVERTISEMENT
Avoid posting medical records, membership numbers or photographs containing personal information on public social media. Share them through the provider’s or insurer’s established channels.
Safety concerns have a separate reporting route.
TMDA’s adverse-reaction guidance provides for reports from healthcare professionals and consumers and includes forms for suspected poor product quality. Its guidance encourages affected consumers to report concerns to healthcare professionals and drug-information centres. A suspected reaction should be assessed clinically; an insurance complaint is not a substitute for medical attention.
The next useful information will be implementation guidance explaining when the linked checks begin, how providers submit claims and how disputed product records are handled. Until those operational details are issued, the reported ministerial direction should be described as a direction to establish verification, rather than a confirmed simultaneous rejection of claims across every insurer.
ADVERTISEMENT
Related Articles
